These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 29180278)

  • 1. Higher versus standard amikacin single dose in emergency department patients with severe sepsis and septic shock: a randomised controlled trial.
    De Winter S; Wauters J; Meersseman W; Verhaegen J; Van Wijngaerden E; Peetermans W; Annaert P; Verelst S; Spriet I
    Int J Antimicrob Agents; 2018 Apr; 51(4):562-570. PubMed ID: 29180278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantification and Explanation of the Variability of First-Dose Amikacin Concentrations in Critically Ill Patients Admitted to the Emergency Department: A Population Pharmacokinetic Analysis.
    De Winter S; van Hest R; Dreesen E; Annaert P; Wauters J; Meersseman W; Van den Eede N; Desmet S; Verelst S; Vanbrabant P; Peetermans W; Spriet I
    Eur J Drug Metab Pharmacokinet; 2021 Sep; 46(5):653-663. PubMed ID: 34297338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of a loading dose of amikacin in septic patients undergoing continuous renal replacement therapy.
    Taccone FS; de Backer D; Laterre PF; Spapen H; Dugernier T; Delattre I; Wallemacq P; Vincent JL; Jacobs F
    Int J Antimicrob Agents; 2011 Jun; 37(6):531-5. PubMed ID: 21489756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal Amikacin Levels for Patients with Sepsis in Intensive Care Unit of Cipto Mangunkusumo Hospital, Jakarta, Indonesia.
    Aliska G; Setiabudy R; Purwantyastuti P; Karuniawati A; Sedono R; Dewi TU; Azwar MK
    Acta Med Indones; 2017 Jul; 49(3):227-235. PubMed ID: 29093233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock.
    Taccone FS; Laterre PF; Spapen H; Dugernier T; Delattre I; Layeux B; De Backer D; Wittebole X; Wallemacq P; Vincent JL; Jacobs F
    Crit Care; 2010; 14(2):R53. PubMed ID: 20370907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Amikacin Pharmacokinetics and Pharmacodynamics for Optimal Initial Dosing Regimen.
    Kato H; Hagihara M; Hirai J; Sakanashi D; Suematsu H; Nishiyama N; Koizumi Y; Yamagishi Y; Matsuura K; Mikamo H
    Drugs R D; 2017 Mar; 17(1):177-187. PubMed ID: 28063020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and pharmacodynamics of meropenem in children with severe infection.
    Kongthavonsakul K; Lucksiri A; Eakanunkul S; Roongjang S; Issaranggoon Na Ayuthaya S; Oberdorfer P
    Int J Antimicrob Agents; 2016 Aug; 48(2):151-7. PubMed ID: 27345269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of in vitro critical inhibitory concentration, a novel approach to predict in vivo synergistic bactericidal effect of combined amikacin and piperacillin against Pseudomonas aeruginosa in a systemic rat infection model.
    Chan E; Zhou S; Srikumar S; Duan W
    Pharm Res; 2006 Apr; 23(4):729-41. PubMed ID: 16554956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015).
    Pfaller MA; Shortridge D; Sader HS; Castanheira M; Flamm RK
    Int J Antimicrob Agents; 2018 Feb; 51(2):181-189. PubMed ID: 28993143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of imipenem and amikacin pharmacokinetic/pharmacodynamic parameters on microbiological outcome of Gram-negative bacilli ventilator-associated pneumonia.
    Pajot O; Burdet C; Couffignal C; Massias L; Armand-Lefevre L; Foucrier A; Da Silva D; Lasocki S; Laouénan C; Mentec H; Mentré F; Wolff M
    J Antimicrob Chemother; 2015 May; 70(5):1487-94. PubMed ID: 25630642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic drug monitoring-guided continuous infusion of piperacillin/tazobactam significantly improves pharmacokinetic target attainment in critically ill patients: a retrospective analysis of four years of clinical experience.
    Richter DC; Frey O; Röhr A; Roberts JA; Köberer A; Fuchs T; Papadimas N; Heinzel-Gutenbrunner M; Brenner T; Lichtenstern C; Weigand MA; Brinkmann A
    Infection; 2019 Dec; 47(6):1001-1011. PubMed ID: 31473974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing Amikacin Dosage in Pediatrics Based on Population Pharmacokinetic/Pharmacodynamic Modeling.
    Alqahtani S; Abouelkheir M; Alsultan A; Elsharawy Y; Alkoraishi A; Osman R; Mansy W
    Paediatr Drugs; 2018 Jun; 20(3):265-272. PubMed ID: 29569124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of the National French recommendations regarding the dosing regimen of 8mg/kg of gentamicin in patients hospitalised in intensive care units.
    Allou N; Allyn J; Levy Y; Bouteau A; Caujolle M; Delmas B; Valance D; Brulliard C; Martinet O; Vandroux D; Montravers P; Augustin P
    Anaesth Crit Care Pain Med; 2016 Oct; 35(5):331-335. PubMed ID: 27133236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What is the optimal loading dose of broad-spectrum β-lactam antibiotics in septic patients? Results from pharmacokinetic simulation modelling.
    Delattre IK; Hites M; Laterre PF; Dugernier T; Spapen H; Wallemacq PE; Jacobs F; Taccone FS
    Int J Antimicrob Agents; 2020 Oct; 56(4):106113. PubMed ID: 32721604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population Pharmacokinetic Study of the Suitability of Standard Dosing Regimens of Amikacin in Critically Ill Patients with Open-Abdomen and Negative-Pressure Wound Therapy.
    Carrié C; Delzor F; Roure S; Dubuisson V; Petit L; Molimard M; Breilh D; Biais M
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31964795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Administration of higher doses of amikacin in early stages of sepsis in critically ill patients.
    Najmeddin F; Ahmadi A; Mahmoudi L; Sadeghi K; Khalili H; Ahmadvand A; Najafi A; Mojtahedzadeh M
    Acta Med Iran; 2014; 52(9):703-9. PubMed ID: 25325208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic drug monitoring of amikacin in septic patients.
    Duszynska W; Taccone FS; Hurkacz M; Kowalska-Krochmal B; Wiela-Hojeńska A; Kübler A
    Crit Care; 2013 Jul; 17(4):R165. PubMed ID: 23886243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Target attainment of cefotaxime in critically ill children with meningococcal septic shock as a model for cefotaxime dosing in severe pediatric sepsis.
    Hartman SJF; Boeddha NP; Ekinci E; Koch BCP; Donders R; Hazelzet JA; Driessen GJ; de Wildt SN
    Eur J Clin Microbiol Infect Dis; 2019 Jul; 38(7):1255-1260. PubMed ID: 30968258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aminoglycosides against carbapenem-resistant Enterobacteriaceae in the critically ill: the pitfalls of aminoglycoside susceptibility.
    Zavascki AP; Klee BO; Bulitta JB
    Expert Rev Anti Infect Ther; 2017 Jun; 15(6):519-526. PubMed ID: 28375030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of pharmacokinetic/pharmacodynamic-derived predictions of antibiotic efficacy with clinical outcomes in severely ill patients with Pseudomonas aeruginosa pneumonia.
    Fish DN; Kiser TH
    Pharmacotherapy; 2013 Oct; 33(10):1022-34. PubMed ID: 23744833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.